{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"ORR of single agent pembrolizumab in subjects with refractory GCTs, determined by sum of complete responses and partial responses for at least 3 months using RECIST 1.1 criteria","groups":[{"description":"Pembrolizumab\n\nPembrolizumab: 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.","id":"OG000","title":"Experimental Arm"}],"populationDescription":"Data for this secondary outcome measure was not collected or analyzed due to the early termination of this study.","reportingStatus":"POSTED","timeFrame":"From the start of treatment D1 every 6 weeks for initial 18 weeks, assessed for up to 52 weeks","title":"Disease Assessment for Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Criteria","type":"SECONDARY"}